Cargando…

Circulating adropin and vascular endothelial growth factor receptor-2 levels in age-related macular degeneration and T2DM patients—A cross-sectional study

BACKGROUND: Macular drusen formation and angiogenesis are the two chief processes associated with age-related macular degeneration. Adropin and vascular endothelial growth factor receptor-2 (VEGFR-2) may be involved in these pathologies. By altering lipid metabolism, adropin may contribute in the ea...

Descripción completa

Detalles Bibliográficos
Autores principales: Neethu, Areekulangara, Jayashree, Kuppuswami, Senthilkumar, Gandhipuram Periyasamy, Ramesh Babu, K, Vadivelan, Mehalingam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652138/
https://www.ncbi.nlm.nih.gov/pubmed/33209815
http://dx.doi.org/10.4103/jfmpc.jfmpc_813_20
_version_ 1783607645197828096
author Neethu, Areekulangara
Jayashree, Kuppuswami
Senthilkumar, Gandhipuram Periyasamy
Ramesh Babu, K
Vadivelan, Mehalingam
author_facet Neethu, Areekulangara
Jayashree, Kuppuswami
Senthilkumar, Gandhipuram Periyasamy
Ramesh Babu, K
Vadivelan, Mehalingam
author_sort Neethu, Areekulangara
collection PubMed
description BACKGROUND: Macular drusen formation and angiogenesis are the two chief processes associated with age-related macular degeneration. Adropin and vascular endothelial growth factor receptor-2 (VEGFR-2) may be involved in these pathologies. By altering lipid metabolism, adropin may contribute in the early stages of age-related macular degeneration (AMD). VEGFR-2 may participate in the later form of AMD, by promoting angiogenesis. This study compared the circulatory levels of adropin and VEGFR-2 in AMD and patients without AMD and assessed their association with disease severity, to understand their possible role in AMD. OBJECTIVES: This study aimed to assess and compare the serum levels of adropin and VEGFR-2 in patients with AMD and type 2 diabetes patients without AMD, and, to investigate the correlation between these two parameters with disease severity. METHODS: Our study involves two groups of 39 each. Group A (age-related macular degeneration) and Group B (diabetes patients without age-related macular degeneration). Routine parameters fasting blood sugar (FBS), lipid profile, and liver function tests (LFT) were estimated by using autoanalyzer. Serum adropin and VEGFR-2 were assessed by ELISA. RESULTS: Among the basic parameters, systolic blood pressure and fasting blood glucose alone were significantly different across the groups. We did not find significant alterations in adropin and VEGFR-2 levels between the study groups. Our lipid profile parameters (triglycerides and total cholesterol) have significant positive association. VEGFR-2 showed a positive correlation with the severity of AMD. Adropin did not exhibit any correlation with disease severity and with VEGFR-2. CONCLUSION: We could not find any observable alterations of statistical significance, in adropin and VEGFR-2 levels. VEGFR-2's correlation with disease severity could be important. Adropin might have subtler roles in AMD, though not evident from our study, and requires a deeper observation at the molecular level to elucidate its function.
format Online
Article
Text
id pubmed-7652138
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-76521382020-11-17 Circulating adropin and vascular endothelial growth factor receptor-2 levels in age-related macular degeneration and T2DM patients—A cross-sectional study Neethu, Areekulangara Jayashree, Kuppuswami Senthilkumar, Gandhipuram Periyasamy Ramesh Babu, K Vadivelan, Mehalingam J Family Med Prim Care Original Article BACKGROUND: Macular drusen formation and angiogenesis are the two chief processes associated with age-related macular degeneration. Adropin and vascular endothelial growth factor receptor-2 (VEGFR-2) may be involved in these pathologies. By altering lipid metabolism, adropin may contribute in the early stages of age-related macular degeneration (AMD). VEGFR-2 may participate in the later form of AMD, by promoting angiogenesis. This study compared the circulatory levels of adropin and VEGFR-2 in AMD and patients without AMD and assessed their association with disease severity, to understand their possible role in AMD. OBJECTIVES: This study aimed to assess and compare the serum levels of adropin and VEGFR-2 in patients with AMD and type 2 diabetes patients without AMD, and, to investigate the correlation between these two parameters with disease severity. METHODS: Our study involves two groups of 39 each. Group A (age-related macular degeneration) and Group B (diabetes patients without age-related macular degeneration). Routine parameters fasting blood sugar (FBS), lipid profile, and liver function tests (LFT) were estimated by using autoanalyzer. Serum adropin and VEGFR-2 were assessed by ELISA. RESULTS: Among the basic parameters, systolic blood pressure and fasting blood glucose alone were significantly different across the groups. We did not find significant alterations in adropin and VEGFR-2 levels between the study groups. Our lipid profile parameters (triglycerides and total cholesterol) have significant positive association. VEGFR-2 showed a positive correlation with the severity of AMD. Adropin did not exhibit any correlation with disease severity and with VEGFR-2. CONCLUSION: We could not find any observable alterations of statistical significance, in adropin and VEGFR-2 levels. VEGFR-2's correlation with disease severity could be important. Adropin might have subtler roles in AMD, though not evident from our study, and requires a deeper observation at the molecular level to elucidate its function. Wolters Kluwer - Medknow 2020-09-30 /pmc/articles/PMC7652138/ /pubmed/33209815 http://dx.doi.org/10.4103/jfmpc.jfmpc_813_20 Text en Copyright: © 2020 Journal of Family Medicine and Primary Care http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Neethu, Areekulangara
Jayashree, Kuppuswami
Senthilkumar, Gandhipuram Periyasamy
Ramesh Babu, K
Vadivelan, Mehalingam
Circulating adropin and vascular endothelial growth factor receptor-2 levels in age-related macular degeneration and T2DM patients—A cross-sectional study
title Circulating adropin and vascular endothelial growth factor receptor-2 levels in age-related macular degeneration and T2DM patients—A cross-sectional study
title_full Circulating adropin and vascular endothelial growth factor receptor-2 levels in age-related macular degeneration and T2DM patients—A cross-sectional study
title_fullStr Circulating adropin and vascular endothelial growth factor receptor-2 levels in age-related macular degeneration and T2DM patients—A cross-sectional study
title_full_unstemmed Circulating adropin and vascular endothelial growth factor receptor-2 levels in age-related macular degeneration and T2DM patients—A cross-sectional study
title_short Circulating adropin and vascular endothelial growth factor receptor-2 levels in age-related macular degeneration and T2DM patients—A cross-sectional study
title_sort circulating adropin and vascular endothelial growth factor receptor-2 levels in age-related macular degeneration and t2dm patients—a cross-sectional study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652138/
https://www.ncbi.nlm.nih.gov/pubmed/33209815
http://dx.doi.org/10.4103/jfmpc.jfmpc_813_20
work_keys_str_mv AT neethuareekulangara circulatingadropinandvascularendothelialgrowthfactorreceptor2levelsinagerelatedmaculardegenerationandt2dmpatientsacrosssectionalstudy
AT jayashreekuppuswami circulatingadropinandvascularendothelialgrowthfactorreceptor2levelsinagerelatedmaculardegenerationandt2dmpatientsacrosssectionalstudy
AT senthilkumargandhipuramperiyasamy circulatingadropinandvascularendothelialgrowthfactorreceptor2levelsinagerelatedmaculardegenerationandt2dmpatientsacrosssectionalstudy
AT rameshbabuk circulatingadropinandvascularendothelialgrowthfactorreceptor2levelsinagerelatedmaculardegenerationandt2dmpatientsacrosssectionalstudy
AT vadivelanmehalingam circulatingadropinandvascularendothelialgrowthfactorreceptor2levelsinagerelatedmaculardegenerationandt2dmpatientsacrosssectionalstudy